Functionally active effector T cells are generated through clonal expansion. Most effector T cells are later eliminated, whereas a small number survive and differentiate into memory T cells. The mechanisms by which some effector T cells escape apoptosis and become memory T cells are not understood. Neuropeptides such as the vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) inhibit antigen-induced apoptosis of CD4 T cells. By using an in vivo long-term experimental model, in which CD4 T cells from TRCtransgenic mice were transferred into hosts, we demonstrate that VIP and PACAP induce the survival and/or generation of antigen-specific CD4 T cells with a memory Th2 phenotype. This was confirmed by the fact that transgenic CD4 T cells were recovered only from mice that received Th2, but not Th1 effector cells, in the presence of VIP or PACAP. In vitro, VIP/PACAP support the survival of Th2, but not Th1, cell lines through an inhibition of antigen-induced apoptosis. The role of neuropeptides in the biased development of Th2 memory cells is particularly relevant in view of the immune deviation existing in immune-privileged sites such as the brain and eye, where Th2, but not Th1, responses occur in nonpathological conditions. Key words: VIP • PACAP • neuroimmunomodulation • memory T cells • apoptosis A significant function of the constantly renewing hematopoietic system is the maintenance of homeostasis. Clonal expansion of antigen-specific lymphocytes leads to the generation of effector cells and is followed by removal of excess cells. Depending on the antigen, T cells are eliminated through two different apoptotic processes: passive and active apoptosis (reviewed in ref 1). Passive apoptosis occurs in the absence of further antigenic stimulation and eliminates T cells at the end of an immune response. Active apoptosis or antigen-induced cell death (AICD) limits the number of T cells in the presence of persistent antigenic stimulation, and requires TCR re-engagement. T cells are resistant to apoptosis following initial TCR engagement but become highly susceptible to apoptosis during the ensuing cell cycling (2, 3). Little is known about the factors and the mechanisms that regulate the shift from an apoptosis-resistant to an apoptosis-sensitive phenotype and vice versa. However, during an immune response, mechanisms must operate not only to destroy no longer needed and potentially damaging T cells, but also to allow the survival of a small number of activated T cells that differentiate into longlived memory cells.
A significant function of the constantly renewing hematopoietic system is the maintenance of homeostasis. Clonal expansion of antigen-specific lymphocytes leads to the generation of effector cells and is followed by removal of excess cells. Depending on the antigen, T cells are eliminated through two different apoptotic processes: passive and active apoptosis (reviewed in ref 1) . Passive apoptosis occurs in the absence of further antigenic stimulation and eliminates T cells at the end of an immune response. Active apoptosis or antigen-induced cell death (AICD) limits the number of T cells in the presence of persistent antigenic stimulation, and requires TCR re-engagement. T cells are resistant to apoptosis following initial TCR engagement but become highly susceptible to apoptosis during the ensuing cell cycling (2, 3) . Little is known about the factors and the mechanisms that regulate the shift from an apoptosis-resistant to an apoptosis-sensitive phenotype and vice versa. However, during an immune response, mechanisms must operate not only to destroy no longer needed and potentially damaging T cells, but also to allow the survival of a small number of activated T cells that differentiate into longlived memory cells.
Vasoactive intestinal peptide (VIP) and the structurally related pituitary adenylate cyclaseactivating polypeptide (PACAP) are two neuropeptides present in the immune microenvironment (4, 5) that have a broad spectrum of biological functions, including actions on innate and adaptive immunity (5) (6) (7) . Originally, VIP and PACAP were considered as negative regulators of the immune response (6, 8, 9) . However, the effects of these neuropeptides are more complex, depending on the cell type, differentiation stage, and overall activation state, and a more accurate description of the physiological role of VIP and PACAP is their participation in the control of immune homeostasis. Indeed, with regard to T-cell differentiation, we have reported that VIP and PACAP contribute to a preferential Th2 response (10) . Recently, VIP and PACAP were shown to inhibit AICD in peripheral CD4 T cells through the down-regulation of Fas ligand (FasL) expression (11) . In view of these findings, VIP and PACAP are reasonable candidates for the generation of memory T cells following antigen stimulation. Here we show that both neuropeptides promote the in vivo effector function and memory phenotype of Th2, but not Th1, cells by preferentially inhibiting the clonal deletion of Th2 cells. To our knowledge, this is the first report of a neuropeptide on the generation and maintenance of long-lived memory T cells.
MATERIALS AND METHODS

Mice
B10.BR (I-E
k ), C57BL/6 (H-2 b ), and AND TCR transgenic mice were purchased from Jackson Laboratory (Bar Harbor, ME). AND Tg mice express a Vβ3/Vα11 TCR specific for pigeon chytochrome c fragment 88-104 (PCCF) bound to I-E k . In all transfer experiments, we used AND TCR Tg mice on a C57BL/6 background derived by backcrossing a F1 male original AND TCR Tg mouse three to five times to C57BL/6. Transgenic progeny were then crossed to B10.BR. Both male and female F1 expressing the transgenic TCR were used in experiments. Adoptive hosts were C57BL/6 x B10.BR F1 males.
Cell preparations
Purified naïve CD4 T cells from Tg mice were isolated as described previously (11) . The purified T cells were >98% CD4
+ by FACS analysis.
Antigen presenting cells (APC) were prepared by T-cell depletion of B10.BR spleen cells or peritoneal exudate cells by treatment with a mixture of anti-CD8, anti-Th1.2, and anti-CD4 monoclonal antibodies (mAbs) on ice for 10 min, followed by complement-mediated lysis. Purified APCs were treated with 50 µg/ml mitomycin C (Sigma, St. Louis, MO) for 20 min at 37°C.
Effector Th1 and Th2 cells were generated as previously described (12) . In brief, purified naïve CD4 + cells (3 × 10 5 cells/ml) from Tg + mice were cultured with APC (10 5 cells/ml) and PCCF (5 µg/ml) plus IL-2 (50 U/ml). IL-4 (200 U/ml) plus anti-IFNγ Ab (10 µg/ml) for polarization to Th2 effectors, and IFNγ (1000 U/ml) and anti-IL-4 (10 µg/ml) for Th2 effectors, were added at the initiation of culture to achieve optimal growth and complete polarization (12) . After 4 days, Th1 and Th2 effectors were harvested, washed, and restimulated at 5 × 10 5 cells/ml with PCCF (5 µM) and APC (3 × 10 5 cells/ml), in the absence or presence of IL-2 (20 U/ml), and/or VIP (10 -8 M) or PACAP (10 -8 M).
Th1 and Th2 cell lines were established by regular cycles of stimulation with Ag (PCCF, 5 µg/ml) and APC (3 × 10 5 cells/ml) of polarized Th1 and Th2 effectors (5 × 10 5 cells/ml) for 3 days, followed by propagation in IL-2 (20 U/ml) for 5-8 days. The Th cell lines used for adoptive transfer experiments, and long-term cultures were at cycles 3 to 7 (1 to 2 months in culture). Th1 and Th2 cell lines were characterized in terms of cytokine profile following Ag stimulation (Th1 cell lines produced 19 units IL-2/ml, 48 units IFNγ/ml, 3 units IL-4/ml, and <2 units IL-5/ml; Th2 cell lines produced 12 units IL-2/ml, <1 units IFNγ/ml, 129 units IL-4/ml, and 46 units IL-5/ml).
Superantigen-induced clonal deletion
B10.BR mice (groups of five) were injected i.p. with the superantigen staphylococcal enterotoxin A (SEA, 0.15 µg/mouse, Sigma), with or without VIP or PACAP (5 nmol/mouse, Novabiochem, Laufelfingen, Switzerland) for 24 h, followed by two i.p. injections of VIP or PACAP (5 nmol/ml) at 24-h intervals. On days 2, 4, 7, and 12 after SEA injection, spleen and mesenteric lymph node CD4 + T cells (1 × 10 6 cells/ml) were analyzed for the expression of Vβ3 + (responsive to SEA) and Vβ6 + (nonresponsive to SEA, used as control) by flow cytometry.
Adoptive transfer of Tg T cells and Th cell lines
On day -1, AND TCR Tg T cells or Th1 or Th2 cell lines (3 × 10 6 cells) were injected i.v. into normal or thymectomized C57BL/6 × B10.BR F1 recipients. On day 0 and +2, 500 µg PCCF in balanced salt solution was injected i.p., followed immediately by injection of phosphate-buffered saline (PBS) (control) or 5 nmol VIP or PACAP. On days +1 and +3, VIP or PACAP (5 nmol) were also injected i.p. On day 10 (normal mice) and day 62 (thymectomized mice), T cells from spleen and lymph nodes (LN) were isolated and examined for expression of Vβ3, CD44, CD45RB, and L-selectin by flow cytometry or were cultured for cytokine production, ELISPOT assay, and T help assay.
FACS analysis
Cells (1 × 10 6 cells/ml) were harvested in ice-cold RPMI complete medium (RPMI 1640 supplemented with 2 mM L-glutamine, 100 U/ml penicillin, 10 µg/ml streptomycin, and 10% fetal calf serum [FCS] ) and washed twice with PBS containing 0.1% sodium azide plus 2% heatinactivated FCS (wash buffer). The cells were incubated in wash buffer containing 2.5 µg/ml normal mouse immunoglobulin for 15 min, after which anti-Vβ3, anti-Vβ6, anti-Vα11, anti-CD44, anti-CD45RB, or anti-L-selectin mAbs (Pharmingen, San Diego, CA) were added (2.5 µg/ml final concentration), followed by incubation at 4°C for 1 h. The cells were washed and further stained with 2.5 µg/ml of FITC-conjugated goat F(ab') 2 anti-rat IgG, and PE-conjugated anti-mouse CD4 or CD8, for 30 min at 4°C. In some cases, samples were stained with biotinylated hamster anti-mouse Vβ3 Ab, followed by tricolor streptavidin. After extensive washing, we fixed the cells in 1% buffered paraformaldehyde. Stained lymphocytes, gated according to forward-and side-scatter characteristics, were analyzed on a FACScan flow cytometer (Becton Dickinson, Palo Alto, CA). Isotype-matched antibodies were used as controls. Fluorescence data were expressed as mean channel fluorescence (MCF) and as the percentage of positive cells after subtraction of background isotype-matched values.
Cytokine ELISA
Groups of four C57BL/6 × B10.BR F1 mice were adoptively transferred with AND TCR Tg T cells and treated with PCCF, with or without VIP or PACAP as described previously. Sixty-four days after the Ag stimulation, 5 × 10 5 /ml splenocytes were stimulated ex vivo with 5 µM PCCF and 0.5 × 10 5 APC for 24 h. The content of cytokines in supernatants was determined by specific sandwich ELISAs. The Ab pairs (Pharmingen) were as follows: IL-4, BVD4-1D11/BVD6-24G2; IFNγ, R4-6A2/XMG1.2; IL-5, TRFK5/TRFK4; and IL-2, JES6-1A12/JES6-5H4.
ELISPOT assay
Groups of four C57BL/6 × B10.BR F1 mice were transferred with AND TCR Tg T cells and treated with PCCF, with or without VIP or PACAP, as described previously. Sixty-four days after the Ag stimulation, 3 × 10 6 /ml splenocytes were stimulated ex vivo with 5 µM PCCF and 0.5 × 10 6 APC for 24 h. Viable cells were recovered by passage through a Histopaque 1007 density gradient (Sigma). Viable cells were washed and serially diluted, and the frequency of T cells producing IFNγ or IL-4 was determined by ELISPOT according to the supplier's protocol (Pharmingen). Data represent total cytokine-producing cells/10 5 splenocytes, calculated from the serially diluted samples. No spots were detected in unstimulated cultures or in cultures stimulated with an irrelevant Ag (OVA, 100 µg/ml).
Assessment of apoptotic cells
Apoptosis of effector cells was assessed by TUNEL assay, using a fluorescein in situ cell death detection kit (Boehringer Mannheim, Indianapolis, IN) according to the manufacturer's instructions.
Helper assay
Surviving T cells from adoptive transferred mice (day 62) (5 × 10 3 -2 × 10 5 cells/ml) were incubated at with T-depleted B cells from NP-KLH (Sigma; 100 µg/ml in alum-pertussis, i.p. primed B10.BR mice in the presence of NP-PCC (Sigma; 100 ng/ml). Culture supernatants were harvested 10 days later, and NP-specific antibody production was determined.
RESULTS
VIP and PACAP promote survival of Ag-specific CD4 T cells in vivo
We showed previously that VIP and PACAP inhibit Ag-induced cell death in CD4 T cells in vitro (11) . Here we investigate their effects on Ag-induced cell death in vivo. The first model involves administration of a superantigen, which induces deletion of specific effector T cells (13) . B10.BR mice were injected with the superantigen SEA in the presence or absence of VIP or PACAP. On days 2, 5, 7, and 12, spleen and mesenteric lymph node CD4 and CD8 T cells were harvested and analyzed for the expression of Vβ3 TCR (responsive to SEA) and Vβ6 TCR (nonresponsive to SEA). As expected, Vβ3 + CD4 and CD8 T cells expand 4-to 5-fold in the first 48 h following SEA inoculation (Fig. 1a ). This expansion is followed by a massive deletion of Vβ3 + CD4 and CD8 T cells in both spleen and lymph nodes at later times (Fig. 1a) . The nonresponsiveVβ6 + T cells are not affected (on average 8 × 10 5 Vβ6 + CD4 and 5 × 10 5 CD8 T cells in control, SEA-stimulated, and SEA + VIP-treated mice). Treatment with VIP or PACAP results in a marked survival of the Vβ3 + CD4 T cells (Fig. 1a) . In contrast, VIP and PACAP did not prevent the SEA-induced clonal deletion of CD8 T cells (Fig. 1a ).
The second model involves specific peptide antigens. T cells from AND TCR Tg mice recognize a fragment of the pigeon cytochrome (PCCF) in the context of I-E k , and the PCCF-specific T cells can be detected with anti-idiotypic Abs against Vβ3 and Vα11 (14). AND TCR Tg CD4 T cells from nonimmunized Tg mice were adoptively transferred into syngeneic, nontransgenic hosts. The adoptive hosts were stimulated with PCCF in the absence or presence of VIP or PACAP. Seven days after exposure to the Ag, the lymph node and spleen T cells were analyzed in terms of Vβ3/Vα11 markers (Fig. 1b) . Injection with PCCF alone resulted in complete clonal deletion of Ag-specific T cells (Fig. 1b) . Administration of VIP or PACAP concomitantly with PCCF prevented the Ag-induced deletion of Vβ3
+ T cells in both spleen and lymph nodes (Fig. 1b) . Clonal deletion was Ag-dependent because treatment of mice with VIP or PACAP alone, in the absence of Ag, did not significantly affect Vβ3
+ T-cell numbers (Fig. 1b) . These data indicate that VIP and PACAP promote the survival of Ag-specific CD4 T cells in vivo.
VIP and PACAP promote long-term survival of memory Th2 cells
The increased survival of CD4 Ag-specific T cells might lead to higher numbers of Ag-specific memory cells. However, the experiments on Ag-induced apoptosis both in vitro (11) and in vivo (see previous discussion) were short-term. To investigate the long-term effects of VIP and PACAP, we adoptively transferred AND TCR Tg CD4 T cells into syngeneic, nontransgenic recipients. The recipients were thymectomized 2 wk before T-cell transfer to prevent peripheral T-cell repopulation. The adoptive hosts were injected with PCCF in the absence or presence of VIP or PACAP and analyzed for Vβ3/Vα11-bearing T cells 62 days later (Fig. 2a) . VIP and PACAP strikingly enhanced the number of Ag-specific T cells (Fig. 2a) . Therefore, VIP/PACAP exert both a short-term and a long-term protective effect on Ag-specific CD4 T cells in vivo.
Vβ3
+ T cells were harvested from hosts treated with VIP or PACAP and analyzed by flow cytometry. These Vβ3 + T cells exhibited a memory-type phenotype, that is, the cells were small, as assessed by low forward scatter and expressed high levels of CD44 and low levels of Lselectin and CD45RB (Fig. 2b, filled histograms) . In contrast, the Vβ3 -cells recovered from the same recipients (Fig. 2b, open histograms) expressed a naïve-type phenotype, that is, CD44 lo , Lselectin hi , and CD45RB hi , similar to freshly isolated CD4 T cells (Fig. 2b, fresh) . A functional characteristic of memory CD4 T cells is the high level of cytokine production upon restimulation (15) (16) (17) . CD4 T cells were obtained from hosts treated with Ag and VIP or PACAP, or from control mice that did not receive transgenic cells. In was not possible to use adoptive hosts injected only with Ag as controls, since the Ag-specific cells are deleted within a matter of days (Figs. 1b and 2a) . The CD4 T cells harvested 62 days after the adoptive transfer, or from control animals (fresh), were restimulated in vitro with specific Ag (PCCF) and APCs. Culture supernatants were harvested 24 h later, and the cytokine profile was determined. The frequency of Ag-reactive IFNγ-producing and IL-4-producing T cells was also assessed by Elispot. The cells recovered from recipients treated with VIP or PACAP produced markedly higher levels of IL-4 and IL-5 and little IFNγ and IL-2, and they expressed significantly higher frequencies of IL-4-producing T cells ( Fig. 2c and 2d ). These results suggest that VIP/PACAP contribute to the generation of Th2 Ag-specific memory T cells.
This conclusion is supported by another piece of evidence. Th1 and Th2 cells induce a switch to IgG2a/b and IgG1, respectively (16) . To assess the in vitro helper activity of the putative memory T cells from the VIP/PACAP-treated adoptive hosts, the recovered CD4 T cells were mixed with T cell-depleted spleen cells from NP-KLH-primed mice, as a source of haptenprimed B cells. The cultures were stimulated with NP-PCC, and the isotype of the NP-specific Abs was determined in culture supernatants harvested 10 days later. The CD4 T cells from the VIP/PACAP-treated recipients, but not naïve T cells (fresh), provided effective help for IgG1 Ab production (Fig. 2e) .
We next investigated whether the phenotype of the CD4 T cells rescued from SEA-induced clonal deletion by VIP and PACAP is also Th2. Indeed, this is the case, because the T cells recovered from SEA-stimulated mice treated with VIP or PACAP produced higher levels of IL-4 and IL-5 and lower IFNγ and IL-2, and they expressed higher frequencies of IL-4 producing T cells in comparison to mice injected with SEA alone (Fig. 3) .
A critical question is whether Th1 cells never expand under the influence of Ag without or with VIP/PACAP, or do expand and either are sequestered outside spleen and lymph nodes or survive very poorly. To address this question, we determined the number of Th1 and Th2 cells recovered from the short-term in vivo model. AND TCR Tg CD4 T cells from nonimmunized Tg mice were adoptively transferred into syngeneic, nontransgenic hosts. The adoptive hosts were stimulated with PCCF in the absence or presence of VIP or PACAP. Several days after exposure to the Ag, spleen cells were restimulated with Ag and the number of IL-4-and IFNγ-secreting T cells was determined by ELISPOT. Both Ag-specific Th1 and Th2 cells expand in the first 48 h after Ag inoculation in comparison with nonstimulated mice (Fig. 4 ). This expansion is followed by a massive deletion of both Th1 and Th2 cells in spleen at later times (Fig. 4) . Treatment with VIP or PACAP results in a marked survival of the Th2 cells (Fig. 4) . In contrast, VIP and PACAP did not prevent the Ag-induced clonal deletion of Th1 cells (Fig. 4) .
VIP and PACAP selectively induce the proliferation of Th2 cell lines in vivo and in vitro
Established PCCF-specific Th1 and Th2 cell lines derived from AND TCR Tg mice were adoptively transferred into thymectomized syngeneic nontransgenic hosts. The recipients were injected i.p. with PCCF with or without VIP or PACAP, and 62 days later, spleen and lymph node cells were isolated and analyzed by flow cytometry for CD4 and Vβ3 expression. VIP and PACAP promote the survival in vivo of Vβ3 + cells in Th2, but not in Th1-adoptively transferred mice (Fig. 5a) . Similar results were obtained by adoptive transfer into B10.A mice of other established Ag-specific Th1 and Th2 cell lines (18) derived from TCR-Cyt-5CC7-I/Rag2 mice (data not shown). These results confirm the specific effect of VIP/PACAP on Th2 survival.
A differential effect of VIP/PACAP on Th1 and Th2 cells was also observed in vitro. Ag-specific Th1 and Th2 cell lines were stimulated with PCCF and APC in the absence or presence of VIP or PACAP for 8 days and were recultured in fresh medium containing IL-2 with or without VIP or PACAP. Every 7 or 8 days, the viable cells were counted and adjusted to 5 × 10 5 cells/ml, and fresh medium containing IL-2 with or without VIP or PACAP was added. Up to day 28, there were only minor differences in the numbers of Th2 cells cultured in the presence or absence of VIP or PACAP. However, between days 30 and 45, the neuropeptide-treated Th2 cells showed substantial proliferation in contrast to Th2 cells cultured in the absence of VIP or PACAP (Fig.  5b, left panels) . After 45 days, the numbers of Th2 cells cultured in the absence of VIP or PACAP declined, whereas cell numbers of Th2 cells treated with VIP or PACAP continued to increase or remained constant (Fig. 5b, left panels) . In contrast, VIP and PACAP did not prevent the decline in the numbers of long-term grown Th1 cells (Fig. 5b, right panels) . These results confirm that VIP and PACAP prevent specifically Th2 clonal deletion following Ag stimulation. Effector Th2 cells treated with VIP or PACAP in the absence of IL-2 proliferated and survived less than those cultured in the presence of IL-2 (Fig. 5b) , suggesting that IL-2 is a crucial survival factor for these cells and that both VIP/PACAP and IL-2 exert their action on Th2 survival through different synergistic mechanisms.
VIP and PACAP promote Ag-induced CD4 Th2 survival
It has been proposed that polarized effector T cells generated during antigen stimulation give rise to polarized memory T cells (12) . Therefore, a VIP/PACAP positive effect on the survival of effector Th2 cells might be sufficient for promoting the development of Th2 memory cells. AND TCR Tg Th2 effectors were generated in vitro in short-term cultures. The Th2 effectors were restimulated with APC and PCCF with or without IL-2, VIP, or PACAP. The recovered cells were counted and analyzed at different times after restimulation. Th1 and Th2 effectors restimulated with the Ag in the absence of IL-2 did not expand and remained roughly at prestimulation levels (Fig. 6a, left panel) , although, as expected (19) , they secreted high levels of IFNγ and IL-4, respectively (data not shown). Addition of VIP or PACAP during restimulation led to an approximately twofold increase in the number of Th2, but not Th1, cells (Fig. 6a, left  panel) . As previously described (19) , addition of IL-2 led to the expansion of effector cells following Ag stimulation (Fig. 6a, right panels) . Addition of VIP or PACAP to the IL-2-supplemented cultures increased the numbers of Th2 effectors beyond the expansion induced by IL-2 (Fig. 6a, right panel) and continued to support proliferation 2 wk after restimulation (data not shown). Neither VIP nor PACAP increased expansion of IL-2-supplemented Th1 effectors (Fig. 6a, right panels) .
The net cellular expansion is a balance between the increase due to proliferation and the decrease due to cell death. Because VIP and PACAP protect CD4 T cells from antigen-induced apoptosis (11), we investigated their effect on Th1 and Th2 effectors. Th1 and Th2 effectors were restimulated with Ag and APC in the presence or absence of IL-2, VIP, or PACAP, and the percentage of apoptotic CD4 T cells was assessed by the TUNEL assay. Restimulation with Ag alone results in a time-dependent increase in apoptosis, with Th1 cells undergoing apoptosis much faster than Th2 cells (Fig. 6b, left panels) . However, even for Th2, apoptosis of >80% of the cells occurred 7 days after restimulation. Addition of IL-2 reduces Th2 apoptosis (50% vs. 80%) (Fig. 6b, right panels) . VIP and PACAP significantly reduced Th2, but not Th1, apoptosis both in the absence and presence of IL-2 (Fig. 6b) .
DISCUSSION
During a primary immune response, naïve antigen-specific CD4 T cells proliferate and differentiate into effector cells capable of rapidly producing large amounts of cytokines upon restimulation (20) Polarized Th effectors presumably differentiate into polarized memory T cells. Indeed, when Agspecific Th1-and Th2-polarized primary effector T cells were transferred to adoptive hosts, they differentiated into long-lived cells with a memory phenotype, capable of generating a cytokine profile similar to that of the primary effectors (12) . The fact that VIP and PACAP promote the generation of Th2 memory cells could reflect a preferential protective effect for Th2 effectors. Indeed, the two neuropeptides promote the growth and survival of Ag-specific Th2, but not Th1, cells, in long-term cultures.
One of the key events in the generation of memory T cells is the prevention of effector T-cell apoptosis. Our data demonstrates that VIP and PACAP, by themselves or in concert with IL-2, promote the expansion of Ag-specific effector Th2 cells. Furthermore, we show that this effect is due to a decrease in apoptosis rather than to an increase in cell proliferation. This is in agreement with the recently published report that VIP and PACAP prevent AICD in CD4 T cells (11) . Previously, Th2 effectors were shown to undergo both proliferation and cell death upon antigenic stimulation, and IL-2 was shown to support proliferation and partially block apoptosis (19) . VIP and PACAP synergized with IL-2 in promoting Th2 survival and proliferation, and in the presence of both IL-2 and VIP or PACAP, apoptosis was reduced. It is tempting to speculate that whereas IL-2 has a major positive effect on Th2 proliferation, VIP and PACAP significantly inhibit apoptosis, and that the combination of these two mechanisms results in the survival of antigen-specific Th2 cells upon restimulation.
Fas/FasL interactions play an essential role in Ag-induced apoptosis in CD4 T cells (1, 21) . Therefore, agents that inhibit Ag-induced apoptosis may affect FasL and/or Fas expression or interfere with the intracellular Fas-mediated death signaling. The most evident level at which VIP/PACAP may operate is a reduction in Fas and/or FasL expression. Indeed, similar to their effect on anti-CD3-restimulated CD4 T cells and T-cell hybridomas (11, 22) , VIP and PACAP inhibit FasL expression in Ag-restimulated effector Th2 cells (Delgado and Ganea, unpublished results). Also, similar to peripheral CD4 T cells and T-cell hybridomas, Fas expression is only slightly affected. In contrast to Th2 effectors, VIP/PACAP do not significantly affect FasL expression in Th1 effectors (Delgado and Ganea, unpublished results). In addition, resistance to apoptosis in Th2 effectors treated with VIP or PACAP is not associated with the presence of anti-apoptotic molecules such as bcl-2 and FAP-1, a Fas-associated phosphatase that inhibits Fas signaling (23) , because VIP/PACAP do not affect bcl-2 or FAP-1 expression in Th2 cells (Delgado and Ganea, personal communication). Therefore, the positive effect of VIP/PACAP on Th2, but not Th1, effectors correlates with the differential reduction in FasL expression.
Alternatively, the effect of VIP/PACAP on Th2, but not on Th1, effectors might result from differences in the expression of VIP/PACAP receptors. We showed previously that CD4 and CD8 T cells express both VPAC1 and VPAC2 receptors, but not PAC1 receptors (11, 24) . Using quantitative real-time polymerase chain reaction, we have demonstrated that, similar to activated CD4 T cells, Th1 and Th2 cell lines and effectors express VPAC1 and VPAC2 but do not express PAC1 (data not shown). VPAC1 and VPAC2 are coupled primarily to the adenylate cyclase system (25) , and cAMP mediates the inhibitory effects of VIP and PACAP on antigeninduced apoptosis in CD4 T cells (11) . We did not observe any differences in the VIP/PACAPinduced intracellular cAMP levels in Th1 and Th2 cell lines and effectors (data not shown). Therefore, the difference in the effects of VIP/PACAP on Th1 and Th2 clonal deletion is not due to differences in VIP/PACAP receptor expression or cAMP induction.
The positive effect of VIP/PACAP on the survival of Th2 effectors contributes to a prevalent Th2 response. We have recently reported that VIP and PACAP promote a Th2 response in vivo (10) . Several VIP/PACAP-induced mechanisms could contribute to this effect, that is, the induction of B7.2, but not B7.1, in macrophages (10); down-regulation of IL-12 (a cytokine essential for Th1 differentiation) (26) ; and induction of JunB (27) , a positive transactivator for IL-4 (a cytokine essential for Th2 differentiation) (28) . In this context, the VIP/PACAP protection of Th2 cells from apoptosis could play a major role in introducing a bias toward Th2 differentiation.
As far as we know, this is the first report of neuropeptides that support specifically the generation and maintenance of Th2 effectors and memory cells. The only other endogenous factor previously suggested to induce effector T-cell expansion and generation of memory T cells is TGFβ (19) . Similar to VIP and PACAP, TGFβ inhibits FasL expression and reduces AICD (29, 30) .
Previous reports indicated that VIP and PACAP act primarily as endogenous antiinflammatory agents. The two neuropeptides, which are released within the lymphoid organs upon antigenic stimulation (18, 31) , inhibit the production of classical proinflammatory agents such as tumor necrosis factor α, IL-6, NO, IL-12, and the costimulatory function and B7.1/B7.2 expression in activated macrophages (7) (8) (9) and reduce T-cell proliferation and IL-2 production (6). However, recent studies suggest a subtler immunoregulatory role. Whereas VIP and PACAP suppress Th1-and macrophage-derived inflammatory responses, they promote the generation and long-term survival of Th2 cells. This is particularly relevant in view of the concept that immune privilege in organs such as the brain and eye is an active process of immune deviation mediated by regulatory T cells generated in the presence of Th2-derived cytokines (32, 33) . It is tempting to speculate that neuropeptides such as VIP and PACAP, which are abundant in these immuneprivileged sites, play an essential role in maintaining immune deviation. This is supported by the fact that immune privilege in the eye strictly depends on the presence of intact corneal nerves being lost upon nerve severing and regained once the nerves regrow (34) . + T cells (3×10 6 /ml) from AND TCR Tg mice were adoptively transferred into individual C57BL/6 x× B10.BR F1 mice (four mice per group). Twenty-four hours after transfer, mice were i.p. injected with medium or with Ag (PCCF, 500 µg) with or without VIP and PACAP (5 nmol). Ten days after initial Ag stimulation, spleen and lymph node cells were isolated, stained for CD4 and the Tg TCR by using the clonotypic monoclonal antibody (mAb) KJ25, and analyzed by flow cytometry. The results represent the mean number of cells ± SD from three experiments. + T cells (3×10 6 /ml) from AND TCR Tg mice were adoptively transferred into thymectomized C57BL/6 × B10.BR F1 mice on day -1. On days 0 and +2, mice were injected i.p. with medium or with Ag (PCCF, 500 µg), and with or without VIP and PACAP (5 nmol). VIP and PACAP were also administered on days +1 and +3. Sixty-two days after initial Ag stimulation, spleen and lymph node cells were isolated and analyzed for CD4 and the Tg TCR by using the clonotypic mAb KJ25. The results represent the mean number of cells ± SD from one representative experiment of three involving four mice per group. Established PCCF-specific Th1 and Th2 cell lines (3×10 6 /ml) were adoptively transferred into thymectomized C57BL/6 × B10.BR F1 mice. Twenty-four hours after transfer, mice were injected i.p. with medium or with Ag (PCCF, 500 µg), and with or without VIP or PACAP (5 nmol), as described in . At days 2, 4, and 7, the percentage of apoptotic cells was determined by using the TUNEL assay. The results are the mean ± SD of three independent experiments.
